Details of the Drug

General Information of Drug (ID: DMBCIXL)

Drug Name
Stamulumab
Synonyms
MYO-028; MYO-029; RK-35; GDF-8 program, Wyeth BioPharma/Genetics Institute; Anti-myostatin antibody, MetaMorphix/Cambridge Antibody Technology/Wyeth; GDF-8 program, MetaMorphix/Cambridge Antibody Technology/Wyeth; GDF-8 program, MetaMorphix/Wyeth BioPharma/Cambridge Antibody Technology
Indication
Disease Entry ICD 11 Status REF
Duchenne dystrophy 8C70 Phase 1/2 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D0C6IQ

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Growth/differentiation factor 8 (GDF-8) TTSWPH8 GDF8_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Duchenne dystrophy
ICD Disease Classification 8C70
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Growth/differentiation factor 8 (GDF-8) DTT MSTN 1.64E-01 -0.06 -0.06
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT00104078) Study Evaluating MYO-029 in Adult Muscular Dystrophy. U.S. National Institutes of Health.
2 Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care. 2013 November; 7(4): 352-360.